By Fineline Cube Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s TQB2102, a Class 1 innovative drug, has been granted Breakthrough Therapy Designation (BTD) by the National Medical Products Administration (NMPA) for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have not received chemotherapy in the recurrent or metastatic setting.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Sino Biopharmaceutical Limited (HKG: 1177) / Chia Tai Tianqing Pharmaceutical |
| Product | TQB2102 |
| Classification | Class 1 innovative drug |
| Regulatory Status | Breakthrough Therapy Designation (BTD) from NMPA |
| Indication | Unresectable or metastatic HER2-low breast cancer (no prior chemotherapy in recurrent/metastatic setting) |
| Announcement Date | 3 Aug 2026 |
Drug Profile & Mechanism of Action
- Molecule Type: Next-generation HER2 biepitope bispecific antibody-drug conjugate (ADC)
- Development Status: Independently developed by Sino Biopharmaceutical Group
- Target Population: Adult patients with HER2-low breast cancer (IHC 1+ or IHC 2+/ISH-)
- Treatment Setting: First-line in recurrent or metastatic setting (no prior chemotherapy)
Clinical Development Pipeline
Multiple Phase III clinical studies are currently underway for TQB2102 across various indications:
- Advanced HER2-low breast cancer without prior chemotherapy
- Advanced HER2-positive breast cancer following failed anti-HER2 therapy
- Neoadjuvant treatment for HER2-positive breast cancer
- First-line treatment for advanced HER2-positive breast cancer
- Late-line treatment for advanced HER2-positive biliary tract cancer
- Advanced HER2-positive colorectal cancer in patients who have failed prior oxaliplatin, irinotecan, and fluoropyrimidine-based regimens
Strategic Significance
The Breakthrough Therapy Designation provides Chia Tai Tianqing with enhanced communication channels with NMPA reviewers and eligibility for rolling review processes. This regulatory milestone represents a significant step forward in the company’s oncology pipeline and validates the clinical potential of TQB2102.
HER2-low breast cancer represents a significant unmet medical need, as these patients typically do not benefit from traditional HER2-targeted therapies but may respond to next-generation ADCs like TQB2102. The BTD status is granted to drug candidates that demonstrate substantial improvement over existing therapies for serious or life-threatening conditions.
Market Opportunity & Competitive Landscape
- HER2-Low Breast Cancer Burden: Represents approximately 50-60% of all breast cancer cases, creating a substantial addressable market
- Current Treatment Limitations: Limited effective targeted options for HER2-low patients in first-line metastatic setting
- Competitive Positioning: TQB2102’s biepitope design differentiates it from other HER2-targeted ADCs
- Commercial Potential: Breakthrough designation often translates to faster market entry and premium pricing opportunities
Company Pipeline Strategy
“TQB2102’s breakthrough therapy designation underscores our commitment to developing innovative cancer treatments that can meaningfully improve patient outcomes,” said a company spokesperson. “We look forward to working closely with the NMPA to expedite the development timeline and bring this promising therapy to patients in need.”
Sino Biopharmaceutical has been strategically expanding its oncology portfolio through both internal development and strategic partnerships, with several candidates currently in late-stage clinical trials.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory pathways, and commercial expectations for TQB2102. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.-Fineline Info & Tech